Dupilumab is Efficacious in Young Children with Atopic Dermatitis Regardless of Type 2 Comorbidities.

Saved in:
Bibliographic Details
Title: Dupilumab is Efficacious in Young Children with Atopic Dermatitis Regardless of Type 2 Comorbidities.
Authors: Boguniewicz M; University of Colorado School of Medicine, Aurora, CO, USA. boguniewiczm@njhealth.org.; Division of Allergy-Immunology, Department of Pediatrics, National Jewish Health, Denver, CO, USA. boguniewiczm@njhealth.org., Sher LD; Peninsula Research Associates, Rolling Hills Estates, CA, USA., Paller AS; Departments of Dermatology and Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, IL, USA., Arkwright PD; Lydia Becker Institute of Immunology & Inflammation, University of Manchester, Manchester, UK., Yoshihara S; Department of Pediatrics, School of Medicine, Dokkyo Medical University, Tochigi, Japan., Chen Z; Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA., Shah P; Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA., Marco AR; Sanofi, Madrid, Spain.
Source: Advances in therapy [Adv Ther] 2024 Dec; Vol. 41 (12), pp. 4601-4616. Date of Electronic Publication: 2024 Oct 29.
Publication Type: Journal Article; Randomized Controlled Trial; Multicenter Study; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Health Communications Inc Country of Publication: United States NLM ID: 8611864 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1865-8652 (Electronic) Linking ISSN: 0741238X NLM ISO Abbreviation: Adv Ther Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
Description
ISSN:1865-8652
DOI:10.1007/s12325-024-02998-4